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Abstract
Background: Methicillin-resistant Staphylococcus remains a serious problem in the treatment of periprosthetic joint
infection (PJI). Higher failure rates were reported when vancomycin was used in 2-stage exchange arthroplasty. Therefore
a better therapeutic drug is needed to treat PJI caused by methicillin-resistant organisms. The purpose of the study was
to evaluate the safety and efficacy of daptomycin when administered in bone cement combined with systemic use for
methicillin-resistant Staphylococci PJI.
Methods: We conducted a retrospective study from January 2010 to December 2012. Twenty-two patients (10
knees and 12 hips) with PJI caused by methicillin-resistant Staphylococcus species underwent 2-stage revision
arthroplasty. In the first stage, 10 % daptomycin (weight daptomycin per weight bone cement) was incorporated into
polymethylmethacrylate bone cement, and systemic daptomycin (6 mg/kg) was administered postoperatively
for 14 days. In the second stage, 2.5 % w/w daptomycin was used in the bone cement. The minimum follow-up was
2 years or until recurrence of infection.
Results: The infecting organisms included methicillin-resistant Staphylococcus aureus in 10 patients, methicillin-resistant
Staphylococcus epidermidis in 8 patients and methicillin-resistant coagulase-negative Staphylococci in 4 patients. The
mean follow-up duration was 33.7 months (range, 24–51 months). The treatment success rate was 100 %. Only one
patient developed asymptomatic transient elevation of the creatine phosphokinase level. No patient experienced any
adverse effects related to daptomycin such as myositis, rhabdomyolysis, peripheral neuropathy, derangement of liver
function, or eosinophilic pneumonia.
Conclusions: In this series, no serious adverse events occurred. Our protocol, using daptomycin-impregnated
cement combined with short duration of systemic daptomycin, appears to be an effective and safe treatment
for methicillin-resistant Staphylococcus PJI.
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Background
Periprosthetic joint infections (PJI) of the hip and knee
are disastrous complications that occur in approximately
1 to 2 % of patients after total joint arthroplasties [1].
The management of PJI may require long-term anti-
biotic suppression, surgical debridement, one-stage or 2-
stage revision, resection arthroplasty, arthrodesis, or
amputation. The “gold standard” treatment for chronic
PJI in North America is 2-stage revision [2]. The proced-
ure consists of removal of the infected prosthesis in the
first stage, followed by replacing it with a high-dose anti-
biotic cement spacer to eradicate the infection and pre-
vent joint space contracture between stages [3]. Once the
infection has been treated with systemic antibiotics, the
second stage is performed to implant a new prosthesis.
Most PJI are caused by Gram-positive cocci, including
Staphylococcus species [4]. Methicillin-resistant organisms
account for up to 74 % of PJI in some reports [5]. Vanco-
mycin is most commonly incorporated into polymethyl-
methacrylate (PMMA) bone cement and subsequently
used intravenously for the treatment of methicillin-
resistant Staphylococcus aureus (MRSA) [6]. The success-
ful clinical control of chronic PJI due to methicillin-
resistant organisms varies from 48 to 89 % [7, 8] in the hip
and 60 to 74 % [9, 10] in the knee when vancomycin is
used in 2-stage exchange arthroplasty. These results have
led orthopedic surgeons to seek new therapeutic strategies
for PJI caused by methicillin-resistant Staphylococcus spp.
Daptomycin is a novel cyclic lipopeptide antibiotic
secreted by Streptomyces roseosporus. Daptomycin has
excellent activity against Gram-positive bacteria through
disruption of multiple bacterial plasma membrane func-
tions, without penetrating the cytoplasm [11]. Clinical
experience with daptomycin treatment of PJI is limited
to systemic intravenous use in small case series [12–14].
Several in vitro studies also showed that daptomycin
could be locally delivered from PMMA bone cement
without impairing cement strength [15, 16]. Only one
clinical report showed combined use of daptomycin in
bone cement and intravenously to treat chronic PJI in a
2-stage surgery [17].
The aim of this study was to review the results of dap-
tomycin used in PMMA bone cement and systemically
in 2-stage exchange surgeries for the treatment of PJI
due to methicillin-resistant Staphylococcus species.
Methods
Study design and setting
This retrospective, descriptive study was conducted
from January 2010 to December 2012 in a 2700-bed
medical center. Consecutive adults who underwent 2-
stage revision arthroplasty using local and systemic
daptomycin for the treatment of PJI caused by methicillin-
resistant Staphylococcus species were included. The use of
local and systemic daptomycin for the treatment of
methicillin-resistant Staphylococcus PJI was just done
during the study period. The exclusion criteria were PJI
caused by methicillin-sensitive Staphylococcus species,
Gram-negative bacteria, Mycobacterium tuberculosis,
fungi and polymicrobial infections. Diagnosis was con-
firmed by isolation of methicillin-resistant bacteria in at
least 2 intraoperative cultures. All clinical data were
collected retrospectively by reviewing electronic medical
records. The Institutional Review Board of the Chang
Gung Memorial Hospital Foundation approved the study
(IRB No. 103-3637B).
Surgical procedures and postoperative care
Patients with early prosthesis infections and acute
haematogenous infections with failure of DAIR sur-
gery (debridement, antibiotics, irrigation and pros-
thesis retention), or with prior implant loosening and
late chronic infections, underwent two-stage revision
surgery [18]. The infecting organisms included MRSA
in 10 patients, methicillin-resistant Staphylococcus epider-
midis (MRSE) in 8 patients and methicillin-resistant co-
agulase-negative Staphylococci (MRCoNS) in 4 patients.
The minimum inhibitory concentrations (MICs) of vanco-
mycin were determined as > 1.5 mg/L in all patients.
Higher vancomycin MICs (>1.5 mg/L) have a higher risk
of treatment failure for MRSA treated with vancomycin
[19]. In the first stage, the operative procedure included
removal of the implants, aggressive debridement of the
joint and insertion of a high-dose, daptomycin-loaded
cement spacer or beads. Twenty (91 %) of the 22 patients
were treated with bead fashion of antibiotic-loaded ce-
ment. Erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), complete blood count (CBC) with differen-
tial and creatine phosphokinase (CPK) were monitored
weekly postoperatively. In the second stage, new pros-
theses were reimplanted and low-dose daptomycin-loaded
cement was used if cementing fixation was needed. No
patients had a joint aspiration before reimplantation. The
criteria for reimplantation included a reduced ESR, return
to near normal CRP, and satisfactory wound status. A
closed suction drain inserted immediately after each
surgery was removed 2–5 days later when the amount of
daily drainage was less than 60 mL per day. The postoper-
ative course of periprosthetic knee infection treatment
consisted of a 3-day period of immobilization in a hinge-
knee brace, followed by gradually continuous passive
motion exercise, and protected weight-bearing activity. All
the revision total hip arthroplasty were posterior
approach. The postoperative course of periprosthetic hip
infection treatment consisted of a 3-day period of
immobilization using skin traction (2 kg) followed by pro-
tected weight-bearing activity under hip abduction and
brace protection to prevent dislocation.
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Composition of bone cement
If the methicillin-resistant microorganism had been
identified at the time of resection arthroplasty, the dose
of daptomycin was 4 g per 40 g package of bone cement
(Stryker Orthopaedics, Mahwah, New Jersey) to reach
therapeutic levels in the joint fluid [20]. If the infecting
microorganism could not be identified preoperatively, a
combination of 4 g of daptomycin and 4 g of ceftazidime
(10 % w/w for each antibiotic) per 40 g package of bone
cement was used. In the second stage, the antibiotic
bone cement spacer or beads were carefully removed.
Intraoperative tissue samples were also taken for culture,
as in the first stage. All reimplantations were performed
after a 2-week antibiotic holiday without elevation of
ESR and CRP. After prophylaxis with intravenous 1 g
vancomycin, the patients underwent prosthesis reim-
plantation with 1 g daptomycin (2.5 % w/w) in a pack of
40 g bone cement [Stryker Orthopaedics, Mahwah, New
Jersey] without decreasing the cement strength [15, 16]
for knee or hip prosthesis fixation. For knee implant-
ation, we usually use 1 g daptomycin in a pack of 40 g
bone cement for tibia and patellar component fixation
and 1 g vancomycin in another pack of bone cement for
femoral component fixation. For hip reimplantation,
three of 12 patients used 1 g daptomycin in a pack of
40 g bone cement for cup fixation.
Microbiological investigation
During the first stage of the 2-stage procedure, at least 3
samples of periprosthetic tissue (synovial membranes or
bone) were obtained for cultures under aerobic and an-
aerobic conditions. One or 2 synovial fluid samples were
put into blood culture flasks to increase sensitivity for
the diagnosis of PJI [21]. All the samples of synovial fluid
or periprosthetic tissue were incubated for at least
14 days [22]. These patients received 14 days of intra-
venous daptomycin 6 mg/kg/day postoperatively.
Definition of outcome
Two-stage reimplantation was defined as being success-
ful if the patient had no symptom or sign of infection
(no pain, swelling, erythema, warmth, wound discharge,
loosening of the prosthesis), had normal CRP and ESR,
and did not require reoperation (including irrigation and
debridement with prosthesis retention and repeat resec-
tion) after a 2-year follow-up [23]. Treatment failure was
defined as: a) death related to the infection; b) recur-
rence of infectious symptoms and signs; c) requiring a
reoperation.
Statistical analysis
Categorical variables were expressed as percentages and
numerical data as medians and ranges. Infection control
rate was calculated for patients treated with daptomycin.
All patients were included in the analysis.
Results
Seventy-six patients had PJI of the knee and hip during
the study period. Twenty-two (10 knees, 12 hips) had
PJI caused by methicillin-resistant Staphylococcus spe-
cies and underwent 2-stage revision arthroplasty, with
daptomycin used in PMMA bone cement and systemic-
ally (Table 1). There were 16 men and 6 women. Two
patients had Staphylococcus aureus bacteremia at first
presentation. The average age at the time of the 2-stage
revision was 64.4 years (range, 38–87 years). The mean
Charlson comorbidity index was 3.95 (range, 2–6). The
surgical procedures before enrolment included primary
hip arthroplasty (10 patients), primary knee arthroplasty
(8), revision total hip arthroplasty (2) and revision total
knee arthroplasty (2). Fourteen subjects underwent de-
bridement with prosthesis retention before the 2-stage
revision. The mean interval between the previous sur-
gery and the first stage of the two-stage revision was 32
(8–120) months. The mean interim period between the
two-stage debridement and reimplantation was averaged
14 weeks (range, 10–18 weeks). There was no breakage
of the cement spacer during the interim. The mean
follow-up duration was 33.7 months (range, 24–57
months). No patient was lost to follow-up. The treat-
ment success rate was 100 % without recurrence of
infection. One patient developed asymptomatic transient
elevation of the CPK level. No adverse effect related to
daptomycin, such as myositis, rhabdomyolysis, periph-
eral neuropathy, derangement of liver function or
eosinophilic pneumonia was observed in our study.
Discussion
Methicillin-resistant Staphylococci remain a challenge
because the current protocol often has inferior results
compared with protocols used with other organisms for
the treatment of PJI [8, 24, 25]. The 2-stage protocol for
resistant organisms has had success rates ranging
between 48 and 89 % [7–10, 24, 25], while the average
success rate for less virulent organisms was 85 % ~ 95 %
[3, 8]. Most protocols used vancomycin and an amino-
glycoside in PMMA bone cement combined with sys-
temic vancomycin for 2 ~ 6 weeks after first-stage
resection arthroplasty [8–10, 26]. To our knowledge, this
study was the first case-series report of daptomycin used
in PMMA bone cement to treat PJI caused solely by
methicillin-resistant Staphylococcus species. Using 4 gm
daptomycin in 40-g PMMA bone cement combined with
subsequent systemic use for 14 days in the first stage,
followed by 1 g daptomycin in 40-g PMMA bone ce-
ment in the second stage, we achieved a 100 % infection
control rate with a mean follow-up of 2.8 years. We
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attributed the results to the readiness of daptomycin re-
lease from the PMMA bone cement and its excellent
bactericidal effect against methicillin-resistant strains.
Hall et al. showed that daptomycin could be released
from PMMA cement at a rate similar to that of vanco-
mycin in vitro study [27]. These results suggested that
local concentrations of daptomycin from daptomycin-
loaded PMMA cement were above the MIC value for
most Gram-positive cocci. The efficacy of daptomycin
against Staphylococci, compared to vancomycin, has
been demonstrated in vivo and in vitro studies. Dapto-
mycin had a higher bactericidal rate than vancomycin
(92 % vs. 70 %) in an in vitro study [28]. Daptomycin
showed greater and more rapid bactericidal activity than
vancomycin in mice infected by MRSA [29]. Systemic
daptomycin also had a higher success rate than vanco-
mycin in 2-stage revision arthroplasty in a randomized
controlled trial [14].
The actual dosage of daptomycin added in the bone
cement as a spacer to treat PJI is unclear. Cortes et al.
reported the first case report of use of daptomycin 10 g
and gentamicin 10 g in the bone cement (each agent at
5 % w/w) in two-stage revision hip surgery for prosthetic
joint infection [17]. In an international consensus meet-
ing on periprosthetic joint infection, 2 g daptomycin
(5 % w/w) was recommended in spacers [30]. Rouse et al.
found that 3 g daptomycin (7.5 % w/w) did not decrease
the tensile or compressive strength of PMMA bone ce-
ment and retained biologic activity after PMMA cement
polymerization in an in vivo rat model [31]. According
to an in vitro study, the mean percentage of daptomycin
elution increased with an increase in daptomycin loading
[2.5, 7.5, and 15.0 % w/w] in PMMA bone cement. There-
fore, we thought higher dose daptomycin (10 % w/w)
in PMMA bone cement to reach local therapeutic levels
for the treatment of PJI due to methicillin-resistant
Staphylococcus species.
The safety of systemic use of daptomycin after resec-
tion arthroplasty is also a concern. Byren et al. [14] used
daptomycin at 6 or 8 mg/kg for 6 weeks after prosthesis
Table 1 Characteristics of patients with periprosthetic joint infections caused by methicillin-resistant Staphylococcus undergoing
2-stage revision arthroplasties
No. Sex Age Surgical procedures CCI Pathogen Antibiotic regimen (bone
cement g/systemic mg/kg)
Use daptomycin in bone
cement at reimplantation (Y/N)
FU (months) Outcome
1 M 65 DAIR for TKA 4 MRSA DAP 4/DAP 6 Y 26 Infection controlled
2 M 51 THA 4 MRSA DAP 4 + CEF 4/DAP 6 N 32 Infection controlled
3 M 72 DAIR for revision TKA 5 MRSE DAP 4/DAP 6 Y 43 Infection controlled
4 M 53 Revision THA 2 MRCoNS DAP 4 + CEF 4/DAP 6 N 42 Infection controlled
5 F 60 TKA 3 MRSA DAP 4 + CEF 4/DAP 6 Y 38 Infection controlled
6 F 80 DAIR for TKA 5 MRSE DAP 4/DAP 6 Y 26 Infection controlled
7 M 66 DAIR for THA 3 MRCoNS DAP 4/DAP 6 N 51 Infection controlled
8 M 44 DAIR for THA 2 MRSE DAP 4/DAP 6 N 42 Infection controlled
9 M 74 DAIR for TKA 4 MRSE DAP 4/DAP 6 Y 25 Infection controlled
10 M 45 DAIR for THA 3 MRSE DAP 4/DAP 6 N 26 Infection controlled
11 M 51 DAIR for THA 4 MRSA DAP 4/DAP 6 Y 44 Infection controlled
12 F 67 TKA 5 MRSA DAP 4 + CEF 4/DAP 6 Y 32 Infection controlled
13 F 86 TKA 5 MRSA DAP 4 + CEF 4/DAP 6 Y 37 Infection controlled
14 M 51 DAIR for THA 5 MRSA DAP 4/DAP 6 N 40 Infection controlled
15 F 86 TKA 5 MRSA DAP 4 + CEF 4/DAP 6 Y 30 Infection controlled
16 F 81 THA 3 MRSA DAP 4 + CEF 4/DAP 6 Y 32 Infection controlled
17 M 81 DAIR for revision TKA 5 MRSE DAP 4/DAP 6 Y 30 Infection controlled
18 M 51 DAIR for revision THA 4 MRCoNS DAP 4/DAP 6 N 31 Infection controlled
19 M 50 DAIR for THA 2 MRSE DAP 4/DAP 6 N 27 Infection controlled
20 M 87 TKA 6 MRSA DAP 4 + CEF 4/DAP 6 Y 24 Infection controlled
21 M 38 DAIR for THA 2 MRSE DAP 4/DAP 6 N 30 Infection controlled
22 M 78 DAIR for revision THA 6 MRCoNS DAP 4/DAP 6 Y 33 Infection controlled
DAIR debridement, antibiotics, irrigation and prosthesis retention, CCI Charlson comorbidity index, DM diabetes mellitus, HTN hypertension, CVA cerebral vascular
accident, TKA total knee arthroplasty, LC liver cirrhosis, RA rheumatoid arthritis, THA total hip arthroplasty, CAD coronary artery disease, BMI body mass index, HBV
hepatic B virus, HCV hepatic C virus, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, ESRD end-stage renal disease, DAP daptomycin,
CEF ceftazidime, MRSA methicillin-resistant Staphylococcus aureus, MRCoNS methicillin-resistant coagulase-negative Staphylococci, MRSE methicillin-resistant
Staphylococcus epidermis, FU follow-up
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removal in a randomized trial. They found 8 % (2 of 25)
adverse events (AEs) in the 6-mg/kg group and 16.7 %
(4 of 24) AEs in the 8-mg/kg group. The AEs included
skin rash, rhabdomyolysis and increase CPK. In another
study, severe side effects (one case of acute renal failure
due to massive rhabdomyolysis, one of eosinophilic
pneumonia and 2 cases of asymptomatic transient CPK
level elevation) were also reported with daptomycin at a
dose of 6.6 mg/kg/day for an average of 44.9 days in the
treatment of PJI [13]. Our group underwent 2-week sys-
temic antibiotic therapy after first-stage surgery without
obviously poorer results than in other reports [32]. By
decreasing the duration of systemic daptomycin use, 21
of 22 patients tolerated the treatment. No patients devel-
oped gastrointestinal or food intolerance. Only one patient
developed asymptomatic transient elevation of the CPK
level. No patient experienced any severe adverse effects
related to daptomycin. Daptomycin also possesses clinical
and practical advantage over vancomycin, like once daily
versus twice daily dosing, less therapeutic drug monitoring
and potential cost savings. We thought a shorter course of
systemic use of daptomycin would be advisable because
the adverse events would be fewer and the infection con-
trol rates would not be compromised.
In this study, we had used prophylactic intravenous
vancomycin combined with local daptomycin for the
treatment of MRSA PJI at reimplantaiton stage. Vanco-
mycin has been known as the drug of choice to prevent
MRSA PJI in primary or reimplantation arthroplasties
following MRSA infection [33, 34]. We did not choose
intravenous daptomycin for 2 reasons. First, we would
like to compare this result with our previous experience
of using systemic and local vancomycin by changing the
topical antibiotic regime only. This could reduce the
confounding effect if systemic daptomycin were used.
Second, our infection control policy precluded us to
supersede the first-line vancomycin to the second-line
daptomycin for systemic use without drug sensitivity test
and minimal inhibition concentration test.
The study has limitations. First, it was a retrospective
design, and we could not know what proportion of pa-
tients would fail the two-stage protocol if vancomycin
were used. The evaluation of a prospective cohort com-
paring daptomycin to vancomycin may be warranted in
the future. Second, the sample size was small, making it
difficult to obtain statistically significant results. Third,
the optimal ratio of daptomycin to PMMA cement
in vivo study was unknown, and we did not check the
daptomycin level in the joint fluid. The strength of our
study is that it offered clinical data from a cohort of pa-
tients, and reported the safe use of daptomycin in
PMMA cement and intravenously in 2-stage revision
surgery. But further studies are required to evaluate the
long-term outcomes.
Conclusions
In conclusion, daptomycin-impregnated cement com-
bined with a short duration of systemic daptomycin ap-
pears to be an effective treatment for methicillin-resistant
Staphylococci PJI. The protocol could lessen the AEs
related to daptomycin and provided satisfactory infection
control rates.
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